Amgen Inc.

Cytokinetics, Inc.

F.i.s. Fabbrica Italiana Sintetici S.p.a.

Neil Fred Langille

Alan Martin Allgeier

Sheng Cui

Karthik Nagapudi

Henry Morrison

Steven Mennen

Charles Bernard

Karl Bennett Hansen

Shawn D Walker

Jacqueline C S Woo

Bradley Paul Morgan

Alex R Muci

Jason S Tedrow

Robert Ronald Milburn

Matthew G Beaver

Alessandro Arena

Simone Spada

Carolyn Cohen

Jacqueline Woo

Jonathan Vinh-Phu Truong

Provided herein are processes for synthesizing Mcl-1 inhibitors and intermediates such as compound Z that can be used to prepare them. In particular, provided herein are processes for synthesizing compound A1, and salts or solvates thereof and compound A2, and salts and solvates thereof.

Synthesis of sulfonamide intermediates

Provided herein are processes for synthesizing apremilast comprising reacting 3-acetamidophthalic anhydride and (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethan-1-amine or a salt thereof to form apremilast. Also provided are processes for isolating apremilast from the reaction mixture, as described herein.

Process for synthesizing apremilast

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use.

Salt of omecamtiv mecarbil and process for preparing salt

Provided are omecamtiv mecarbil dihydrochloride salt forms, compositions and pharmaceutical formulations thereof, and methods for their preparation and use. Omecamtiv mecarbil (AMG 423, CK-1827452), having the structure: 

Growing community of inventors

Sudbury, MA, United States of America

Neil Fred Langille